Blood pressure drugs improve ulcerative colitis treatment outcomes
Researchers analyzed data from 1,300 patients across two clinical trials of vedolizumab, marketed as Entyvio. They also examined health records for 9,000 patients diagnosed with both ulcerative colitis and hypertension.
Patients who took ACE inhibitors or ARBs alongside vedolizumab faced a lower risk of severe complications requiring hospitalization or colectomy surgery compared to other patients. This clinical benefit appeared exclusively with vedolizumab and did not transfer to other inflammatory bowel disease treatments or alternate blood pressure medications.
Biological mechanisms behind treatment resistance
To investigate why advanced therapies fail in certain patients, the research team examined tissue biopsies and blood samples. Resistance stems from a specific inflammatory pathway affecting blood vessels in the colon, which is the exact biological target of ACE inhibitors and ARBs.
The findings indicate that targeting this vascular inflammation pathway enhances drug efficacy. However, researchers said that clinical trials must determine whether patients with normal blood pressure can safely utilize this mechanism without experiencing dangerous drops in blood pressure.
Future diagnostic tests and clinical trials
The research team is developing a biomarker-based diagnostic test to help physicians identify patients who will respond to vedolizumab beforehand. This test aims to spare other patients months of ineffective treatments.
Additional clinical trials remain necessary to confirm these hypotheses and to explore the potential development of new drugs that target this biological pathway without lowering blood pressure.
Frequently Asked Questions
What is vedolizumab and how is it used?
Vedolizumab, known commercially as Entyvio, is a biologic therapy prescribed to treat ulcerative colitis, the most common type of inflammatory bowel disease affecting young people.
Which blood pressure medications showed benefits in the study?
The study identified ACE inhibitors and ARBs as the specific classes of blood pressure drugs that improve vedolizumab treatment outcomes and reduce severe complications.
How many patients were included in the research?
Researchers analyzed data from 1,300 participants across two clinical trials alongside healthcare data from 9,000 patients suffering from both ulcerative colitis and hypertension.
Related reading